Human Breast Cancer Copy Number PCR Array

 ProductSpeciesTechnologyCat. No.Breast Cancer qBiomarker Copy Number PCR ArraysHumanCopy NumberVAHS-0055Z 
The Human Breast Cancer qBiomarker Copy Number PCR Array profiles the copy number of 23 genes reported to undergo frequent genomic alterations in human breast tumor DNA. DNA copy number changes in breast cancer cells have prognostic impact. For example, HER2 amplification and overexpression defines the HER2+ subgroup of breast cancer patients and is both a prognostic marker for poor outcome and a predictive marker for response to anti-HER2 targeted therapies. The genes on the array encode receptors, kinases, phosphatases, and transcription factors that regulate processes such as the cell cycle, growth factor signaling, and cell adhesion. Genes were chosen from the most frequently amplified or deleted genes relevant to oncogenic pathways and breast cancer biology based on the primary literature and public databases. This array may serve as a useful tool to help classify breast cancer samples by genotype and help verify breast cancer phenotypic biomarkers. The array analyzes each gene in each sample in quadruplicate and includes a stable multi-copy reference assay for accurate copy number determination via appropriate DNA input normalization. The simplicity of the product format and operating procedure allow routine and reliable copy number profiling in any research laboratory with access to a real-time PCR instrument.
The qBiomarker Copy Number PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.
96-well Plate, 384-well (4 × 96) Plate, and 100-well Disc formats are available.    



Modify this Array    Gene TableER+/PR+, HER2: CCND1.
Gain in ER+ Tumors: AURKA.
HER2+: ERBB2.
Inflammatory Breast Cancer: ERBB2, MTDH, MYC, PTK2, RB1.
Lapatinib Sensitivity: CDKN2A, EGFR, ERBB2.
AKT & PI-3-Kinase Signaling: AKT1, PPAPDC1B, PTEN.
Apoptosis: BCL2L1, MTDH.
Cell Adhesion & Cytoskeleton: CSMD1, PAK1, PTK2.
Cell Cycle: AURKA, BCL2L1, CCND1, CDK4, CDKN2A, RB1.
DNA Repair: C11orf30 (EMSY), TOP2A.
Drug Metabolism: BCHE.
NFKB Signaling: MTDH.
Receptor Tyrosine Kinases: EGFR, ERBB2, FGFR1, FGFR2.
Transcription Factors and Co-Factors: MTDH, MYC, NCOA3, RB1, TFDP1.

 
 

Modify this Array    Gene TableER+/PR+, HER2: CCND1.
Gain in ER+ Tumors: AURKA.
HER2+: ERBB2.
Inflammatory Breast Cancer: ERBB2, MTDH, MYC, PTK2, RB1.
Lapatinib Sensitivity: CDKN2A, EGFR, ERBB2.
AKT & PI-3-Kinase Signaling: AKT1, PPAPDC1B, PTEN.
Apoptosis: BCL2L1, MTDH.
Cell Adhesion & Cytoskeleton: CSMD1, PAK1, PTK2.
Cell Cycle: AURKA, BCL2L1, CCND1, CDK4, CDKN2A, RB1.
DNA Repair: C11orf30 (EMSY), TOP2A.
Drug Metabolism: BCHE.
NFKB Signaling: MTDH.
Receptor Tyrosine Kinases: EGFR, ERBB2, FGFR1, FGFR2.
Transcription Factors and Co-Factors: MTDH, MYC, NCOA3, RB1, TFDP1.

 

 
 
ER+/PR+, HER2: CCND1.
Gain in ER+ Tumors: AURKA.
HER2+: ERBB2.
Inflammatory Breast Cancer: ERBB2, MTDH, MYC, PTK2, RB1.
Lapatinib Sensitivity: CDKN2A, EGFR, ERBB2.
AKT & PI-3-Kinase Signaling: AKT1, PPAPDC1B, PTEN.
Apoptosis: BCL2L1, MTDH.
Cell Adhesion & Cytoskeleton: CSMD1, PAK1, PTK2.
Cell Cycle: AURKA, BCL2L1, CCND1, CDK4, CDKN2A, RB1.
DNA Repair: C11orf30 (EMSY), TOP2A.
Drug Metabolism: BCHE.
NFKB Signaling: MTDH.
Receptor Tyrosine Kinases: EGFR, ERBB2, FGFR1, FGFR2.
Transcription Factors and Co-Factors: MTDH, MYC, NCOA3, RB1, TFDP1